Moderna’s vaccine appears to be safe in adolescents, according to the company.
In a phase 2/3 trial of 3732 children ages 12 to 17 in the United States, blood tests showed that an immune response was produced by the vaccine on the same level seen in adults. The trial didn’t specifically look at the efficacy of the vaccine, but it was noted that no child contracted the virus starting 14 days after the second dose. The company says that figures can still shift as more data is gathered. The tests showed the vaccine to be 93 percent effective at preventing mild doses of COVID after one dose. Moderna announced the results Tuesday in a news release, and the results have not yet been peer reviewed or published.
The company said they did not find any significant safety concerns. Side effects included headache, fatigue, muscle pain and chills after administration of the second dose. Pain at the injection site was also sometimes observed. Moderna plans to submit their findings and a request for authorization to the U.S. Food and Drug Administration in early June. Currently, Pfizer’s COVID-19 vaccine is the only one to have gained emergency use authorization from the FDA to include 12- to 15-year-olds.
READ MORE UNBIASED NEWS AT FBANEWS.ORG
ARTICLE: DUSTIN RODGERS
POLITICS EDITOR: CARSON CHOATE
PHOTO CREDITS: WALL STREET JOURNAL
Latest posts by Carson Choate (see all)
- Kyle Rittenhouse says he liked Andrew Yang, but now wants to ‘stay out of politics’ - November 26, 2021
- Man who fatally shot Ahmaud Arbery testifies in his own defense, describes encounter as ‘Life or Death’ - November 18, 2021
- San Francisco woman arrested for alleged thefts of more than $40,000 from Target - November 18, 2021